1887
Letter Open Access
Like 0
Preview this article:

There is no abstract available.

Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2023.28.4.2300044
2023-01-26
2024-02-25
http://instance.metastore.ingenta.com/content/10.2807/1560-7917.ES.2023.28.4.2300044
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/28/4/eurosurv-28-4-5.html?itemId=/content/10.2807/1560-7917.ES.2023.28.4.2300044&mimeType=html&fmt=ahah

References

  1. World Health Organization (WHO). Evaluation of COVID-19 vaccine effectiveness: interim guidance, 17 March 2021. Geneva: WHO; 2021. Available from: https://apps.who.int/iris/handle/10665/340301
  2. Netherlands to reopen further with coronavirus entry passes. The Hague: Government of the Netherlands; 2021. Available from: https://www.government.nl/latest/news/2021/09/14/netherlands-to-reopen-further-with-coronavirus-entry-passes
  3. Arashiro T, Arima Y, Muraoka H, Sato A, Oba K, Uehara Y, et al. COVID-19 vaccine effectiveness against symptomatic SARS-CoV-2 infection during Delta-dominant and Omicron-dominant periods in Japan: a multi-center prospective case-control study (FASCINATE study). Clin Infect Dis. 2022;ciac635.  https://doi.org/10.1093/cid/ciac635  PMID: 35918782 
Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error